本帖最后由 老马 于 2013-3-13 13:43 编辑 " J$ i3 g, f3 p! B/ p. V
& I) y1 v2 h7 |2 m2 P& `+ W4 G
健择（吉西他滨）+顺铂+阿瓦斯汀 x! p, Z% _ F. h6 ?3 ]
Gemzar +Cisplatin + Avastin u8 x& ^0 l/ E& N6 ~4 B/ |3 v
http://annonc.oxfordjournals.org/content/21/9/1804.full# x; t5 X2 \0 Q3 K$ y
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
2 e+ g; r% L6 dPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
7 _' _" I, x6 u1 C/ Y9 G% Q! rResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
1 O+ }+ z( c; {: ^3 B5 i/ Y
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 628)
, ]# f: ?8 |* o; N$ B# O" o华为网盘附件：$ B, k6 p w1 T+ D
【华为网盘】ava.JPG
2 o5 o) f/ X% R3 w |
肺癌历经手术-复发-脑转移，如今母亲
讲述者：一只阿狸整理者：pear
熟悉我家的朋友都知道，我母亲虽然是IB期肺癌，但是很
肺癌新疗法来袭！客观缓解率80%，双
作者：seacat
氟泽雷塞（商品名：达伯特®）是劲方医药开发的KRAS G12C 小分子抑制剂
急急急，求方案，希望得到大家的帮助
群里的老师们，请问如果肾转移会左侧腰以上痛吗？已经痛了有半个多月。一开始痛的时候
与myc结合亲和力高的已上市药物
MYC有所谓不可成药性，还没有专门的靶向药上市。
目前针对myc实际可行的治疗策略是根
67岁父亲肺腺癌4A期 L858R-伏美替尼
病情：
24年4月底我父亲因为呼吸不畅就医，抽胸水、做穿刺活检、做基因检测，结论
显身卡
